Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2021, with a specific reporting date of February 10, 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Instrument | Transaction Type | Price per Share | Total Volume | Transaction Date |
|---|---|---|---|---|
| Ordinary Shares (25p each) | Acquisition under Share Reward Plan | £12.717 | 198 Shares (Aggregated) | 2021-02-09 |
Note: The total volume of 198 shares is derived from the sum of individual transactions listed in the filing (11 executives acquired 20 shares each, and one executive acquired 18 shares).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents routine equity compensation acquisitions by senior management.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed on the London Stock Exchange (XLON) and represent standard participation in the company's share reward scheme.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs and PCAs during the reporting period (198 shares total).
- Confirm the transaction price of £12.717 per share aligns with the market price on February 9, 2021.
- Review the specific roles of the 12 individuals involved to assess the breadth of executive participation in the Share Reward Plan.
- Note that this filing does not provide data on GSK's overall financial performance; refer to Form 20-F for comprehensive financial results.